Drug Misses Type 1 Goal, but May Help Beta Cells

ADA 2011 — SAN DIEGO — Although treatment with the monoclonal antibody teplizumab doesn't appear to improve glycemic control or reduce insulin dose among patients with type 1 diabetes, it may still preserve beta-cell function, researchers said here.


< Back to Listings